Lexaria Bioscience Corp held its annual shareholder meeting on January 14, 2025, with 9,761,279 shares represented, where various directors were elected and executive compensation proposals were voted on, with most receiving strong approval percentages ranging from 54% to 98%. Notably, Chris Bunka and John Docherty were elected with 89% and 98% approval respectively.